Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine

Sponsor
The Cleveland Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT02996227
Collaborator
(none)
532
1
2
34
15.7

Study Details

Study Description

Brief Summary

Comparison of Bilateral Transversus Abdominis Plane Block with Exparel versus Continuous Epidural Analgesia With Bupivacaine

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

The investigator goal is to compare the analgesic efficacy of TAP blocks with liposomal bupivacaine (Exparel) and continuous epidural blocks in patients who are scheduled for major lower abdominal surgery. To assess whether TAP block with Exparel is noninferior to continuous epidural analgesia on pain management, defined as noninferior for both pain control and total opioid consumption for 72 hours, in patients who had major lower abdominal surgery.

Study Design

Study Type:
Interventional
Actual Enrollment :
532 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comparison of Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine: A Randomized, Controlled Trial
Study Start Date :
Dec 1, 2016
Actual Primary Completion Date :
Jun 1, 2019
Actual Study Completion Date :
Oct 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: TAP block with Exparel

Bilateral Transversus Abdominis Plane (TAP) block procedure following injection of liposomal bupivacaine (Exparel)

Procedure: TAP block
Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.

Drug: EXPAREL
Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
Other Names:
  • Liposomal Bupivacaine
  • Active Comparator: Epidural analgesia with Bupivacaine

    Epidural catheters with an infusion of Bupivacaine standard solution without additives

    Procedure: Epidural analgesia
    Epidural catheters will be inserted preoperatively.

    Drug: Bupivacaine
    Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
    Other Names:
  • Marcaine
  • Outcome Measures

    Primary Outcome Measures

    1. VRS Pain score [Discharge from PACU until 72 hours after the end of surgery]

      Pain scores will be measured using a Verbal Response Scale (VRS). VRS is a scale from 0 to 10 where 0 signifies no pain and 10 signifies worst pain ever experienced. The VRS will be recorded every 30 minutes in the recovery area for the first 2 hours, then every 4 hours thereafter while awake for 72 hours.

    2. Total opioid consumption [Discharge from PACU until 72 hours after the end of surgery]

      Opioid consumption will be measured as the total amount of opioids (converted to morphine sulfate equivalents) used during the 72 hours after the end of surgery.

    Secondary Outcome Measures

    1. Activity after surgery [Discharge from PACU until 72 hours after the end of surgery]

      ViSi mobile (Sotera Wireless) patient monitoring system, a platform for comprehensive vital sign monitoring will be used to quantify patient activity over the initial 72 postoperative hours. This system continuously measures position (lying versus sitting) and activity.

    2. Opioid related side effect [The first, second and third postoperative mornings]

      We will use 4-point Opioid-Related Symptom Distress Scale (ORSDS) to evaluate opioid-related side effect. ORSDS questionnaires will be administered by a trained research fellow.

    3. Blood pressure [Discharge from PACU until 72 hours after the end of surgery]

      Visi mobile patient monitoring system will be used to obtain blood pressure of the patient for 72 hours.

    4. Quality of recovery after anesthesia [The first and third postoperative mornings]

      Quality of recovery will be measured using QoR scale. Patients will be questioned on morning of POD1 and 3.

    5. Length of hospital stay [From date of hospital admission until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 100 weeks]

      The length of hospital stay will be measured as days.

    6. Total cost of care [From date of hospital admission until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 100 weeks]

      The total cost of hospital stay will be collected at hospital discharge day or date of death from any cause, which comes first, assessed up to 100 weeks.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Written informed consent

    • 18-85 years old

    • ASA Physical Status 1-3

    • Scheduled for elective open or laparoscopic abdominal surgery, including colorectal and hysterectomy surgeries

    • Anticipated hospitalization of three nights

    • Expected requirement for parenteral opioids for at least 72 hours for postoperative pain

    • Able to use IV PCA systems.

    Exclusion Criteria:
    • Hepatic disease, e.g. twice the normal levels of liver enzymes

    • Kidney disease, e.g. twice the normal level of serum creatinine

    • Bupivacaine sensitivity or known allergy

    • Women who are pregnant or breastfeeding

    • Anticoagulants considered to be a contraindication for epidural or TAP blocks.

    • Surgeries with high port sites will be excluded

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cleveland Clinic Foundation Cleveland Ohio United States 44195

    Sponsors and Collaborators

    • The Cleveland Clinic

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    The Cleveland Clinic
    ClinicalTrials.gov Identifier:
    NCT02996227
    Other Study ID Numbers:
    • 16-1449 -EXPLANE Block
    First Posted:
    Dec 19, 2016
    Last Update Posted:
    Jan 18, 2020
    Last Verified:
    Jan 1, 2020
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 18, 2020